Why Would Investigating Excess Deaths be Bad for Business?
Inconvenient data for big business.
When data relevant to the public is considered "commercially sensitive", it makes you wonder which side the regulators are on?
Excess mortality in England and English regions: March 2020 to December 2023
The UK Office for National Statistics (ONS) has calculated that there were 7.2% or 44,255 more deaths registered in the UK in 2022 based on comparison with the five year average (excluding 2020).1 This persisted into 2023 with 8.6% or 28,024 more deaths registered in the first six months of the year than expected.
Pearson-Stuttard, Jonathan, et al. "Excess mortality in England post COVID-19 pandemic: implications for secondary prevention." The Lancet Regional Health–Europe 36 (2024).
Please support my research efforts by subscribing to Vejon Health Substack. Your support allows me to continue bringing you my insights in a timely and effective way.
Dr McMillan - your first sentence is spot on! I'd like to think the reputation of gov't agencies is in the toilet, but too many are invested in the lies. They'll believe anything.
I used to work in pharma. One of the jobs I had involved communicating externally, explaining the business. Of course some details were commercially sensitive, and couldn’t be shared. For vaccines, these usually related to price, volumes we could manufacture, and contracting with payors.
Tell you what was NEVER commercially sensitive though: pharmacovigilence data. It had to be reported to the regulators, and if necessary, the product would have its safety label updated, or it could end up being withdrawn from the market.